000			01666 a2200517 4500
005			20250513233206.0
264		0	_c20010628
008			200106s 0 0 eng d
022			_a0340-6245
040			_aNLM _beng _cNLM
100	1		_avan der Bom, J G
245	0	0	_aActivation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. _h[electronic resource]
260			_bThrombosis and haemostasis _cFeb 2001
300			_a234-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnalysis of Variance
650	0	4	_aAntifibrinolytic Agents _xadverse effects
650	0	4	_aAntithrombin III
650	0	4	_aArterial Occlusive Diseases _xblood
650	0	4	_aCase-Control Studies
650	0	4	_aCerebrovascular Disorders _xblood
650	0	4	_aCohort Studies
650	0	4	_aCoronary Disease _xblood
650	0	4	_aCross-Sectional Studies
650	0	4	_aFemale
650	0	4	_aFibrin Fibrinogen Degradation Products _xmetabolism
650	0	4	_aFibrinolysin
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPeptide Fragments _xblood
650	0	4	_aPeptide Hydrolases _xblood
650	0	4	_aPeripheral Vascular Diseases _xblood
650	0	4	_aProthrombin
650	0	4	_aVascular Diseases _xblood
650	0	4	_aalpha-2-Antiplasmin
700	1		_aBots, M L
700	1		_aHaverkate, F
700	1		_aMeijer, P
700	1		_aHofman, A
700	1		_aKluft, C
700	1		_aGrobbee, D E
773	0		_tThrombosis and haemostasis _gvol. 85 _gno. 2 _gp. 234-9
999			_c11183432 _d11183432